Highlights of Ophthalmology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Related articles

VOLUME 45 , ISSUE 2ENG ( Apr-2017, 2017 ) > List of Articles

Highlights over Laser Treatment for Diabetic Retinopathy

Samuel H. Yun, Ron A. Aldeman

Citation Information : Yun SH, Aldeman RA. Highlights over Laser Treatment for Diabetic Retinopathy. 2017; 45 (2ENG):11-19.

DOI: 10.5005/highlights-45-2-11

Published Online: 29-01-2021

Copyright Statement:  Copyright © 2017; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

PDF Share
  1. Geneva: World Health Organization; 2012. World Health Organization. Global Data on Visual Impairments 2010.
  2. Scanlon PH, Aldington SJ, Stratton IM. Epidemiological issues in diabetic retinopathy. Middle East Afr J Ophthalmol. 2013;20:293-
  3. [PMC free article] [PubMed]
  4. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin epidemiologic study of diabetic retinopathy XXIII: The twenty-fiveyear incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009;116:497-503. [PMC free article] [PubMed]
  5. Chen E, Looman M, Laouri M, Gallagher M, Van Nuys K, Lakdawalla D, et al. Burden of illness of diabetic macular edema: Literature review. Curr Med Res Opin. 2010;26:1587-97. [PubMed]
  6. Einstein A. Zur quantentheorie der strahlung. Physiol Zool. 1917;18:121-8.
  7. Schawlow A, Townes C. Infrared and optical masers. Phys Rev. 1958;112:1940-9.
  8. Meyer-Schwickerath G. Photo-coagulation of the ocular fundus and the retina. Ann Ocul (Paris) 1956;189:533-48. [PubMed]
  9. Maiman T. Stimulated optical radiation in ruby. Nature. 1960;187:493-4.
  10. L'Esperance FA., Jr An opthalmic argon laser photocoagulation system: Design, construction, and laboratory investigations. Trans Am Ophthalmol Soc. 1968;66:827-904. [PMC free article] [PubMed]
  11. L'Esperance FA., Jr Clinical photocoagulation with the krypton laser. Arch Ophthalmol. 1972;87:693-700. [PubMed]
  12. Castillejos-Rios D, Devenyi R, Moffat K, Yu E. Dye yellow vs. argon green laser in panretinal photocoagulation for proliferative diabetic retinopathy: A comparison of minimum power requirements. Can J Ophthalmol. 1992;27:243-4. [PubMed]
  13. Krauss JM, Puliafito CA. Lasers in ophthalmology. Lasers Surg Med. 1995;17:102-59. [PubMed]
  14. Amirikia A, Puliafito CA. Lasers for vitreoretinal disease. In: Regillo CD, Brown GC, Flynn HW Jr, editors. Vitreoretinal Disease: The Essentials. New York: Thieme Medical Publishers Inc; 1999. pp. 609- 29.
  15. Blumenkranz MS. The evolution of laser therapy in ophthalmology: A perspective on the interactions between photons, patients, physicians, and physicists: The LXX Edward Jackson Memorial Lecture. Am J Ophthalmol. 2014;158:12-25.e1. [PubMed]
  16. Sramek C, Paulus Y, Nomoto H, Huie P, Brown J, Palanker D. Dynamics of retinal photocoagulation and rupture. J Biomed Opt. 2009;14:034007. [PubMed]
  17. Beetham WP, Aiello LM, Balodimos MC, Koncz L. Ruby-laser photocoagulation of early diabetic neovascular retinopathy: Preliminary report of a long-term controlled study. Trans Am Ophthalmol Soc. 1969;67:39-67. [PMC free article] [PubMed]
  18. Zweng HC, Little HL, Peabody RR. Argon laser photocoagulation of diabetic retinopathy. Arch Ophthalmol. 1971;86:395-400. [PubMed]
  19. Photocoagulation treatment of proliferative diabetic retinopathy: The second report of diabetic retinopathy study findings. Ophthalmology. 1978;85:82-106. [PubMed]
  20. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study research group. Ophthalmology. 1991;98(Suppl 5):766-85. [PubMed]
  21. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 2. Early Treatment Diabetic Retinopathy Study research group. Ophthalmology. 1987;94:761-74. [PubMed]
  22. Fong DS, Girach A, Boney A. Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: A literature review. Retina. 2007;27:816-24. [PubMed]
  23. Foulds WS, Kaur C, Luu CD, Kek WK. A role for photoreceptors in retinal oedema and angiogenesis: An additional explanation for laser treatment? Eye (Lond) 2010;24:918-26. [PubMed]
  24. Matsumoto M, Yoshimura N, Honda Y. Increased production of transforming growth factor-beta 2 from cultured human retinal pigment epithelial cells by photocoagulation. Invest Ophthalmol Vis Sci. 1994;35:4245-52. [PubMed]
  25. Sramek C, Mackanos M, Spitler R, Leung LS, Nomoto H, Contag CH, et al. Non-damaging retinal phototherapy: Dynamic range of heat shock protein expression. Invest Ophthalmol Vis Sci. 2011;52:1780-7. [PubMed]
  26. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115:1447-9.e1. [PMC free article] [PubMed]
  27. Diabetic Retinopathy Clinical Research Network (DRCR. net) Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009;127:245-51. [PMC free article] [PubMed]
  28. Scott IU, Danis RP, Bressler SB, Bressler NM, Browning DJ, Qin H, et al. Effect of focal/grid photocoagulation on visual acuity and retinal thickening in eyes with non-center-involved diabetic macular edema. Retina. 2009;29:613-7. [PMC free article] [PubMed]
  29. Kim JW, Ai E. Diabetic retinopathy. In: Regillo CD, Brown GC, Flynn HW Jr, editors. Vitreoretinal Disease: The Essentials. New York: Thieme Medical Publishers Inc; 1999. pp. 133-59.
  30. Arnarsson A, Stefánsson E. Laser treatment and the mechanism of edema reduction in branch retinal vein occlusion. Invest Ophthalmol Vis Sci. 2000;41:877-9. [PubMed]
  31. Ogata N, Ando A, Uyama M, Matsumura M. Expression of cytokines and transcription factors in photocoagulated human retinal pigment epithelial cells. Graefes Arch Clin Exp Ophthalmol. 2001;239:87-95. [PubMed]
  32. Ogata N, Tombran-Tink J, Jo N, Mrazek D, Matsumura M. Upregulation of pigment epithelium-derived factor after laser photocoagulation. Am J Ophthalmol. 2001;132:427-9. [PubMed]
  33. Spranger J, Hammes HP, Preissner KT, Schatz H, Pfeiffer AF. Release of the angiogenesis inhibitor angiostatin in patients with proliferative diabetic retinopathy: Association with retinal photocoagulation. Diabetologia. 2000;43:1404-7. [PubMed]
  34. Xiao M, McLeod D, Cranley J, Williams G, Boulton M. Growth factor staining patterns in the pig retina following retinal laser photocoagulation. Br J Ophthalmol. 1999;83:728-36. [PMC free article] [PubMed]
  35. Akduman L, Olk RJ. Subthreshold (invisible) modified grid diode laser photocoagulation in diffuse diabetic macular edema (DDME) Ophthalmic Surg Lasers. 1999;30:706-14. [PubMed]
  36. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology. 1991;98:1594-602. [PubMed]
  37. Olk RJ. Modified grid argon (blue-green) laser photocoagulation for diffuse diabetic macular edema. Ophthalmology. 1986;93:938-
  38. [PubMed]
  39. Olk RJ. Argon green (514 nm) versus krypton red (647 nm) modified grid laser photocoagulation for diffuse diabetic macular edema. Ophthalmology. 1990;97:1101-12. [PubMed]
  40. Striph GG, Hart WM, Jr, Olk RJ. Modified grid laser photocoagulation for diabetic macular edema. The effect on the central visual field. Ophthalmology. 1988;95:1673-9. [PubMed]
  41. Fong DS, Strauber SF, Aiello LP, Beck RW, Callanan DG, et al. Writing Committee for the Diabetic Retinopathy Clinical Research Network. Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol. 2007;125:469-80. [PMC free article] [PubMed]
  42. Blumenkranz MS, Yellachich D, Andersen DE, Wiltberger MW, Mordaunt D, Marcellino GR, et al. Semiautomated patterned scanning laser for retinal photocoagulation. Retina. 2006;26:370-6. [PubMed]
  43. Jain A, Blumenkranz MS, Paulus Y, Wiltberger MW, Andersen DE, Huie P, et al. Effect of pulse duration on size and character of the lesion in retinal photocoagulation. Arch Ophthalmol. 2008;126:78-
  44. [PubMed]
  45. Muqit MM, Gray JC, Marcellino GR, Henson DB, Young LB, Patton N, et al. In vivo laser-tissue interactions and healing responses from 20- vs 100-millisecond pulse Pascal photocoagulation burns. Arch Ophthalmol. 2010;128:448-55. [PubMed]
  46. Muqit MM, Gray JC, Marcellino GR, Henson DB, Young LB, Patton N, et al. Barely visible 10-millisecond pascal laser photocoagulation for diabetic macular edema: Observations of clinical effect and burn localization. Am J Ophthalmol. 2010;149:979-986.e2. [PubMed]
  47. Nagpal M, Marlecha S, Nagpal K. Comparison of laser photocoagulation for diabetic retinopathy using 532-nm standard laser versus multispot pattern scan laser. Retina. 2010;30:452-8. [PubMed]
  48. Al-Hussainy S, Dodson PM, Gibson JM. Pain response and followup of patients undergoing panretinal laser photocoagulation with reduced exposure times. Eye (Lond) 2008;22:96-9. [PubMed]
  49. Muqit MM, Marcellino GR, Gray JC, McLauchlan R, Henson DB, Young LB, et al. Pain responses of Pascal 20 ms multi-spot and 100 ms single-spot panretinal photocoagulation: Manchester Pascal Study, MAPASS report 2. Br J Ophthalmol. 2010;94:1493-8. [PubMed]
  50. Chappelow AV, Tan K, Waheed NK, Kaiser PK. Panretinal photocoagulation for proliferative diabetic retinopathy: Pattern scan laser versus argon laser. Am J Ophthalmol. 2012;153:137-42.e2. [PubMed]
  51. Palanker D, Lavinsky D, Blumenkranz MS, Marcellino G. The impact of pulse duration and burn grade on size of retinal photocoagulation lesion: Implications for pattern density. Retina. 2011;31:1664-
  52. [PubMed]
  53. Friberg TR, Karatza EC. The treatment of macular disease using a micropulsed and continuous wave 810-nm diode laser. Ophthalmology. 1997;104:2030-8. [PubMed]
  54. Akduman L, Olk RJ. Diode laser (810 nm) versus argon green (514 nm) modified grid photocoagulation for diffuse diabetic macular edema. Ophthalmology. 1997;104:1433-41. [PubMed]
  55. Rutledge BK, Wallow IH, Poulsen GL. Sub-pigment epithelial membranes after photocoagulation for diabetic macular edema. Arch Ophthalmol. 1993;111:608-13. [PubMed]
  56. Laursen ML, Moeller F, Sander B, Sjoelie AK. Subthreshold micropulse diode laser treatment in diabetic macular oedema. Br J Ophthalmol. 2004;88:1173-9. [PMC free article] [PubMed]
  57. Luttrull JK, Musch DC, Mainster MA. Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema. Br J Ophthalmol. 2005;89:74-80. [PMC free article] [PubMed]
  58. Kumar V, Ghosh B, Mehta DK, Goel N. Functional outcome of subthreshold versus threshold diode laser photocoagulation in diabetic macular oedema. Eye (Lond) 2010;24:1459-65. [PubMed]
  59. Luttrull JK, Spink CJ. Serial optical coherence tomography of subthreshold diode laser micropulse photocoagulation for diabetic macular edema. Ophthalmic Surg Lasers Imaging. 2006;37:370-7. [PubMed]
  60. Luttrull JK, Musch DC, Spink CA. Subthreshold diode micropulse panretinal photocoagulation for proliferative diabetic retinopathy. Eye (Lond) 2008;22:607-12. [PubMed]
  61. Luttrull JK, Sinclair SH. Safety of transfoveal subthreshold diode micropulse laser for fovea-involving diabetic macular edema in eyes with good visual acuity. Retina. 2014;34:2010-20. [PubMed]
  62. Figueira J, Khan J, Nunes S, Sivaprasad S, Rosa A, de Abreu JF, et al. Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. Br J Ophthalmol. 2009;93:1341-4. [PubMed]
  63. Lavinsky D, Cardillo JA, Melo LA, Jr, Dare A, Farah ME, Belfort R., Jr Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema. Invest Ophthalmol Vis Sci. 2011;52:4314-23. [PubMed]
  64. Sivaprasad S, Elagouz M, McHugh D, Shona O, Dorin G. Micropulsed diode laser therapy: Evolution and clinical applications. Surv Ophthalmol. 2010;55:516-30. [PubMed]
  65. Lavinsky D, Sramek C, Wang J, Huie P, Dalal R, Mandel Y, et al. Subvisible retinal laser therapy: Titration algorithm and tissue response. Retina. 2014;34:87-97. [PubMed]
  66. Kernt M, Cheuteu R, Vounotrypidis E, Haritoglou C, Kampik A, Ulbig MW, et al. Focal and panretinal photocoagulation with a navigated laser (NAVILAS®) Acta Ophthalmol. 2011;89:e662-4. [PubMed]
  67. Neubauer AS, Langer J, Liegl R, Haritoglou C, Wolf A, Kozak I, et al. Navigated macular laser decreases retreatment rate for diabetic macular edema: A comparison with conventional macular laser. Clin Ophthalmol. 2013;7:121-8. [PMC free article] [PubMed]
  68. Kozak I, Oster SF, Cortes MA, Dowell D, Hartmann K, Kim JS, et al. Clinical evaluation and treatment accuracy in diabetic macular edema using navigated laser photocoagulator NAVILAS. Ophthalmology. 2011;118:1119-24. [PubMed]
  69. Kernt M, Ulbig M, Haritoglou C. Seattle, Washington: The Association for Research in Vision and Ophthalmology; 2013. Combination of ranibizumab and navigated retinal photocoagulation vs ranibizumab mono-therapy for diabetic macular oedema: Twelve month results.
  70. Barteselli G, Kozak I, El-Emam S, Chhablani J, Cortes MA, Freeman WR. 12-month results of the standardised combination therapy for diabetic macular oedema: Intravitreal bevacizumab and navigated retinal photocoagulation. Br J Ophthalmol. 2014;98:1036-41. [PMC free article] [PubMed]
  71. Chhablani J, Mathai A, Rani P, Gupta V, Arevalo JF, Kozak I. Comparison of conventional pattern and novel navigated panretinal photocoagulation in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 2014;55:3432-8. [PubMed]
  72. Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: Report 2. Ophthalmology. 2010;117:1078-1086.e2. [PubMed]
  73. Michaelides M, Fraser-Bell S, Hamilton R, Kaines A, Egan C, Bunce C, et al. Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): Report 1. Retina. 2010;30:781-6. [PubMed]
  74. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615-25. [PubMed]
  75. Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Salehipour M, Yaseri M, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology. 2009;116:1142-50. [PubMed]
  76. Soheilian M, Garfami KH, Ramezani A, Yaseri M, Peyman GA. Twoyear results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina. 2012;32:314-21. [PubMed]
  77. Diabetic Retinopathy Clinical Research Network. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064-1077.e5. [PMC free article] [PubMed]
  78. Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL, 3rd, Friedman SM, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609-14. [PMC free article] [PubMed]
  79. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, et al. Primary end point (six months) results of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2009;116:2175-81.e1. [PubMed]
  80. Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010;117:2146-51. [PubMed]
  81. Giani A, Cigada M, Choudhry N, Deiro AP, Oldani M, Pellegrini M, et al. Reproducibility of retinal thickness measurements on normal and pathologic eyes by different optical coherence tomography instruments. Am J Ophthalmol. 2010;150:815-24. [PubMed]
  82. Mitchell P, Annemans L, Gallagher M, Hasan R, Thomas S, Gairy K, et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: Evidence from the RESTORE trial. Br J Ophthalmol. 2012;96:688-93. [PMC free article] [PubMed].
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.